Buy Rating for Aquestive Therapeutics Driven by Anaphylm’s FDA Approval Prospects and Market Potential

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Aquestive Therapeutics, with a price target of $10.00.

Ram Selvaraju has given his Buy rating due to a combination of factors surrounding Aquestive Therapeutics’ Anaphylm product. The anticipation of the FDA’s decision on Anaphylm, expected by January 31, 2026, plays a significant role. Anaphylm is poised to be the first FDA-approved, non-invasive, orally delivered epinephrine product for severe allergic reactions, offering a needle-free alternative that could address patient hesitancy associated with injections. The completion of 11 clinical studies and the FDA’s waiver of the advisory committee further bolster confidence in a favorable approval outcome.
Additionally, Aquestive’s strategic preparations for Anaphylm’s launch, including market access optimization and global expansion efforts, enhance the product’s commercial prospects. The company is expanding its infrastructure and meeting key milestones to ensure a successful launch. The potential for Anaphylm to achieve peak sales exceeding $280 million by 2034, coupled with its convenience advantage over existing treatments, underscores the positive outlook. These factors collectively justify the Buy rating and the 12-month price target of $10.

Selvaraju covers the Healthcare sector, focusing on stocks such as Emergent Biosolutions, Bioxcel Therapeutics, and Vanda. According to TipRanks, Selvaraju has an average return of 23.3% and a 51.40% success rate on recommended stocks.

In another report released on November 7, Piper Sandler also maintained a Buy rating on the stock with a $8.00 price target.